A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2015

At a glance

  • Drugs Atreleuton (Primary)
  • Indications Acute coronary syndromes
  • Focus Biomarker; Therapeutic Use
  • Acronyms FDG-PET
  • Most Recent Events

    • 14 Jun 2012 Additional company (Tallikut Pharmaceuticals) added in association as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top